BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics


BioCryst Pharmaceuticals, Inc. (BCRX): $15.46

0.76 (+5.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 508

in industry

BCRX POWR Grades


  • Growth is the dimension where BCRX ranks best; there it ranks ahead of 65.02% of US stocks.
  • BCRX's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • BCRX ranks lowest in Momentum; there it ranks in the 4th percentile.

BCRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for BCRX is -0.75 -- better than just 4.35% of US stocks.
  • BCRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 2.27% of US stocks.
  • With a year-over-year growth in debt of 249.48%, Biocryst Pharmaceuticals Inc's debt growth rate surpasses 96.03% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biocryst Pharmaceuticals Inc are LOGC, CRIS, OMER, SVRA, and GSIT.
  • Visit BCRX's SEC page to see the company's official filings. To visit the company's web site, go to www.biocryst.com.

BCRX Valuation Summary

  • In comparison to the median Healthcare stock, BCRX's EV/EBIT ratio is 155.97% lower, now standing at -16.4.
  • Over the past 243 months, BCRX's EV/EBIT ratio has gone down 11.7.
  • BCRX's EV/EBIT ratio has moved down 11.7 over the prior 243 months.

Below are key valuation metrics over time for BCRX.

Stock Date P/S P/B P/E EV/EBIT
BCRX 2021-08-31 36.0 -26.8 -13.3 -16.4
BCRX 2021-08-30 35.5 -26.5 -13.1 -16.1
BCRX 2021-08-27 35.4 -26.4 -13.1 -16.1
BCRX 2021-08-26 34.7 -25.9 -12.8 -15.8
BCRX 2021-08-25 35.0 -26.1 -12.9 -15.9
BCRX 2021-08-24 34.9 -26.1 -12.9 -15.9

BCRX Growth Metrics

  • Its 4 year net cashflow from operations growth rate is now at -204.15%.
  • Its 2 year net cashflow from operations growth rate is now at -64.28%.
  • Its 4 year cash and equivalents growth rate is now at 595.72%.
BCRX's revenue has moved up $58,483,000 over the prior 30 months.

The table below shows BCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 79.136 -169.316 -214.09
2021-03-31 32.048 -174.946 -209.499
2020-12-31 17.812 -137.216 -182.814
2020-09-30 53.521 -103.025 -124.943
2020-06-30 49.194 -92.407 -116.42
2020-03-31 47.771 -85.867 -115.442

BCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BCRX has a Quality Grade of C, ranking ahead of 62.46% of graded US stocks.
  • BCRX's asset turnover comes in at 0.295 -- ranking 154th of 680 Pharmaceutical Products stocks.
  • BLCM, VIRX, and NWBO are the stocks whose asset turnover ratios are most correlated with BCRX.

The table below shows BCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.295 0.901 -0.933
2021-03-31 0.127 0.766 -1.361
2020-12-31 0.083 0.906 -2.051
2020-09-30 0.305 0.922 -3.095
2020-06-30 0.319 0.946 -2.677
2020-03-31 0.368 0.944 -1.858

BCRX Price Target

For more insight on analysts targets of BCRX, see our BCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.27 Average Broker Recommendation 1.58 (Moderate Buy)

BCRX Stock Price Chart Interactive Chart >

Price chart for BCRX

BCRX Price/Volume Stats

Current price $15.46 52-week high $18.48
Prev. close $14.70 52-week low $3.57
Day low $14.61 Volume 2,624,600
Day high $15.49 Avg. volume 4,365,015
50-day MA $14.96 Dividend yield N/A
200-day MA $13.51 Market Cap 2.77B

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio


Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.


BCRX Latest News Stream


Event/Time News Detail
Loading, please wait...

BCRX Latest Social Stream


Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

Do Hedge Funds Love BioCryst Pharmaceuticals, Inc. (BCRX)?

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

Yahoo | October 25, 2021

BioCryst to Report Third Quarter 2021 Financial Results on November 3

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and

Yahoo | October 20, 2021

7 Best Growth Stocks to Buy and Hold for the Next 10 Years

These growth stocks could become multi-baggers in the future.

Muslim Farooque on InvestorPlace | October 18, 2021

2 Super-Charged Growth Stocks to Buy Now

Growth stocks can be a thing of beauty. The trick, if you will, is to suss out growth stocks that won't rot on the vine, so to speak. While both of these biotech stocks have more than doubled in value in the past three years, I believe each of these healthcare equities still has a lot of room to run in 2022 and beyond.

Yahoo | October 13, 2021

Noteworthy Tuesday Option Activity: BCRX, SGH, AMN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioCryst Pharmaceuticals Inc (Symbol: BCRX), where a total of 17,848 contracts have traded so far, representing approximately 1.8 million underlying shares. That amount

iShook Finance | October 12, 2021

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo 3.62%
3-mo -8.09%
6-mo 27.56%
1-year 302.60%
3-year 115.62%
5-year 258.70%
YTD 107.52%
2020 115.94%
2019 -57.25%
2018 64.36%
2017 -22.43%
2016 -38.66%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7895 seconds.